Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec;45(4):303-12.
doi: 10.4143/crt.2013.45.4.303. Epub 2013 Dec 31.

Immunogenicity of influenza vaccine in colorectal cancer patients

Dong Ho Kim  1 , Yun Yong Lee  2 , Ui Sup Shin  3 , Sun Mi Moon  3
Affiliations

Immunogenicity of influenza vaccine in colorectal cancer patients

Dong Ho Kim et al. Cancer Res Treat. 2013 Dec.

Abstract

Purpose: Although influenza is regarded as a major cause of morbidity and mortality in immunocompromised patients, vaccine coverage remains poor. We evaluated the immunogenicity of influenza vaccines in colorectal cancer patients.

Materials and methods: In this study, 40 colorectal cancer patients who received an influenza vaccine at the Korea Cancer Center Hospital during the 2009-2010 and 2010-2011 influenza seasons were analyzed. The blood samples were collected at prevaccination and 30 days post vaccination, and antibody titers were measured using the hemagglutination-inhibition tests.

Results: In the 2009-2011 season, the seroprotection rate for H1N1 (94.7%) was significantly higher than that for H3N2 (42.1%) and B (47.3%). The seroconversion rate was 52.6%, 26.3%, and 36.8% for H1N1, H3N2, and B, respectively. Fold increase of geometric mean titer (MFI) was 3.86, 1.49, and 3.33 for H1N1, H3N2, and B, respectively. In the 2010-2011 season, the seroprotection rate for H1N1 (57.1%) was significantly higher than that for H3N2 (52.4%) and B (38.1%). The seroconversion rate was 52.4%, 47.6% and 33.3% for H1N1, H3N2, and B, respectively. MFI was 12.29, 3.62 and 4.27 for H1N1, H3N2, and B, respectively.

Conclusion: Our study cohort showed an acceptable immune response to an influenza vaccine without significant adverse effects, supporting the recommendation for annual influenza vaccination in colorectal cancer patients.

Keywords: Colorectal neoplasms; Hemagglutination inhibition tests; Human influenza; Influenza vaccines.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest relevant to this article was not reported.

Figures

Fig. 1
Fig. 1
Linear regression analysis between age of subjects and their hemagglutination inhibition (HI) titer.
Fig. 2
Fig. 2
Linear regression analysis between total chemotherapy duration and their hemagglutination inhibition (HI) titer.
See this image and copyright information in PMC

References

    1. Whitley RJ, Monto AS. Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents. J Infect Dis. 2006;194(Suppl 2):S133–S138. - PubMed
    1. Ljungman P, Andersson J, Aschan J, Barkholt L, Ehrnst A, Johansson M, et al. Influenza A in immunocompromised patients. Clin Infect Dis. 1993;17:244–247. - PubMed
    1. Kumar D, Michaels MG, Morris MI, Green M, Avery RK, Liu C, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis. 2010;10:521–526. - PMC - PubMed
    1. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009;9:493–504. - PMC - PubMed
    1. Beck CR, McKenzie BC, Hashim AB, Harris RC, Zanuzdana A, Agboado G, et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective. PLoS One. 2011;6:e29249. - PMC - PubMed

LinkOut - more resources